-
公开(公告)号:US20180282304A1
公开(公告)日:2018-10-04
申请号:US16008419
申请日:2018-06-14
Applicant: Pfizer Inc.
Inventor: Mark Edward Schnute , Göran Mattias Wennerstål , James Robert Blinn , Neelu Kaila , James Richard Kiefer, JR. , Scot Richard Mente , Ravi G. Kurumbail , Marvin Jay Meyers , Atli Thorarensen , Li Xing , Christoph Wolfgang Zapf , Edouard Zamaratski , Andrew Christopher Flick , Peter Jones
IPC: C07D401/14 , C07D403/04 , C07D413/14 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5355 , C07D401/04 , C07D407/14 , C07D413/04 , C07D405/14 , C07D487/04 , C07D471/04 , C07D417/14
Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
-
公开(公告)号:US20180086736A1
公开(公告)日:2018-03-29
申请号:US15834545
申请日:2017-12-07
Applicant: Pfizer Inc.
Inventor: Mark Edward Schnute , Göran Mattias Wennerstål , James Robert Blinn , Neelu Kaila , James Richard Kiefer, JR. , Scot Richard Mente , Ravi G. Kurumbail , Marvin Jay Meyers , Atli Thorarensen , Li Xing , Christoph Wolfgang Zapf , Edouard Zamaratski , Andrew Christopher Flick , Peter Jones
IPC: C07D401/14 , C07D487/04 , C07D413/14 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5355 , C07D401/04 , C07D407/14 , C07D413/04 , C07D405/14 , C07D403/04 , C07D471/04 , C07D417/14
CPC classification number: C07D401/14 , A61K31/454 , A61K31/497 , A61K31/506 , A61K31/519 , A61K31/5355 , C07D401/04 , C07D403/04 , C07D405/14 , C07D407/14 , C07D413/04 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , Y02A50/406 , A61K2300/00
Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
-
23.
公开(公告)号:US09670201B2
公开(公告)日:2017-06-06
申请号:US14864840
申请日:2015-09-24
Applicant: Pfizer Inc.
Inventor: Mark Edward Schnute , Andrew Christopher Flick , Peter Jones , Neelu Kaila , Scot Richard Mente , John David Trzupek , Michael L. Vazquez , Göran Mattias Wennerstål , Li Xing , Edouard Zamaratski , Liying Zhang
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , C07D471/04 , C07D401/14
CPC classification number: C07D471/04 , C07D401/14
Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating RORγ activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
-
公开(公告)号:US20170071946A1
公开(公告)日:2017-03-16
申请号:US15342601
申请日:2016-11-03
Applicant: Pfizer Inc.
Inventor: Jotham Wadsworth Coe , Christoph Martin Dehnhardt , Peter Jones , Yogesh Anil Sabnis , Joseph Walter Strohbach , Florian Michel Wakenhut , Gavin Alistair Whitlock
IPC: A61K31/519 , A61K31/4725 , A61K31/437
CPC classification number: A61K31/519 , A61K31/437 , A61K31/4725 , C07D471/04 , C07D487/04
Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A and A′ are independently C or N, where C may be unsubstituted or substituted by halo or C1-C6 alkyl; R and R0 are independently selected from the group consisting of H, C1-C6 alkyl, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), and —(CH2)n—W, where W is C3-C8 cycloalkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1-3 N, S and/or O atoms, —SO2—R′, —NHSO2—R′, —NR″SO2—R′ and SR′, where R′ and R″ are independently C1-C6 alkyl or C3-C8 cycloalkyl, etc.; wherein each of said alkyl, cycloalkyl, heterocyclic, phenyl, naphthyl or heteroaryl may be unsubstituted or substituted by phenyl, heteroaryl, etc.; or, R and R0 and the N atom to which they are bonded together form a monocyclic or bicyclic heterocyclic ring which may be unsubstituted or substituted by (a) halo, hydroxy, heteroaryl, C1-C6 alkyl, C1-C6 alkoxy, etc., or (b) —(CH2)n—W, where W is C3-C8 cycloalkyl, phenyl, etc.; R1 is H, halo or cyano; R2 and R2′ are independently H, C1-C6 alkyl, cyano, C1-C6 alkoxy, C1-C6 alkylthio, or C3-C8 cycloalkyl where alkyl, alkoxy, or cycloalkyl is optionally substituted by one or more fluorine atoms; X is a bond, —CO—, —CONH—, —SO2—, —SONH—, or —(CH2)m—; R3 is H, C1-C4 alkyl, phenyl, naphthyl, 5- or 6-membered heteroaryl or heterocyclic containing 1-3 N atoms, a 5-membered heteroaryl or heterocyclic, etc., or (c) 2 O or S atoms and 0-2 N atoms; wherein each of said phenyl, naphthyl, heteroaryl or heterocyclic is optionally substituted by alkyl, 1 substituent —Y—R4 and/or 1-4 substituents each independently selected from R5; with the proviso that when X is —CO— or —SO2—, R3 is not H; Y is a bond, —(CH2)m— or —O—; R4 is (a) H, C1-C6 alkyl, C3-C8 cycloalkyl, halo, oxo, —OR6, —NR7R8, —SR6, —SOR9, —SO2R9, —COR6, —OCOR6, —COOR6, —NR6COR6, —CONR7R8, etc.; (b) phenyl or naphthyl, said phenyl and naphthyl being optionally substituted with 1-5 substituents selected from C1-C6 alkyl, C3-C8 cycloalkyl, halo, cyano, —OR6, —NR7R8, etc.; or (c) a 3 to 8-membered saturated or partially unsaturated monocyclic heteroaryl, etc.; R6 is H, C1-C6 alkyl or C3-C8 cycloalkyl, etc.; R7 and R8 are each independently H, C1-C6 alkyl or C3-C8 cycloalkyl or are taken together with the nitrogen atom to which they are attached to form a 4-, 5- or 6-membered saturated heterocyclic ring containing 1-2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, said C1-C6 alkyl is optionally substituted by C3-C8 cycloalkyl, halo, etc., and said heterocyclic ring being optionally substituted by one or more C1-C6 alkyl or C3-C8 cycloalkyl groups; R9 is C1-C6 alkyl or C3-C8 cycloalkyl; and, m and n are independently 0, 1, 2 or 3. The invention also relates to pharmaceutically acceptable salts of these compounds and to pharmaceutically acceptable solvates thereof; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly asthma and COPD.
-
-
-